Panobinostat’s Questionable Magnitude Of Benefit Can’t Outweigh Toxicities, Panel Says
This article was originally published in The Pink Sheet Daily
Novartis shouldn’t give up on drug for relapsed multiple myeloma, FDA’s Oncologic Drugs Advisory Committee says, even as panel votes against approval based on progression-free survival data.
You may also be interested in...
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
Use of expedited pathway for Biogen's Alzheimer's drug was discussed at a center director briefing in late April, where it garnered backing from several senior CDER officials, as well as CBER director Peter Marks and OCE director Richard Pazdur.
Pink Sheet reporter and editors discuss whether emotion could be removed from US FDA advisory committees, adverse events and advancing science in gene therapy development, and Capitol Hill’s interest in the ongoing user fee negotiations.